Caroline Robert, MD, PhD, on Advanced Melanoma: Research Highlights
ESMO 2018 CongressCaroline Robert, MD, PhD, of Gustave Roussy Cancer Centre, discusses two high-impact studies in stage III melanoma treatment: an update of the COMBI-AD trial examining dabrafenib and trametinib; and neoadjuvant ipilimumab and nivolumab therapy.
Related Videos
Martin Reck, MD, PhD, on Immunotherapy for Thoracic Malignancies: Expert Perspective
Martin Reck, MD, PhD, of the LungenClinic, discusses recent updates on biomarkers beyond PD-L1 expression; mechanisms and management of resistance; as well as combinations an...
Tony Mok, MD, on NSCLC: Targeted Treatment Update
Tony Mok, MD, of the Chinese University of Hong Kong, discusses two important studies in non–small cell lung cancer: FLAURA, which looked at the first-line activity of osimertinib ...
Suresh S. Ramalingam, MD, on Lung Cancer: Research Highlights
Suresh S. Ramalingam, MD, of the Emory University School of Medicine, summarizes the top-line lung cancer results reported at this year’s ESMO Congress, including the role of targe...
Johan F. Vansteenkiste, MD, PhD, on NSCLC: Immunotherapy and Targeted Treatments
Johan F. Vansteenkiste, MD, PhD, of Catholic University Leuven, summarizes a session he co-chaired that included discussion of translating advances in stage IV disease to nonmetast...
Karl Lewis, MD, on Basal Cell Carcinoma: An Ongoing Study
Karl Lewis, MD, of the University of Colorado, discusses a phase II study of cemiplimab in patients with advanced basal cell carcinoma who experienced progression of disease on, or...
